XERS XERS

Xeris Biopharma Stock Price

1.90
0.08 (4.4%)
Upgrade to Real-Time
Afterhours (Closed)
1.90
Volume 917,777
Bid Price 1.84
Ask Price 1.90
News -
Day High 1.94

Low
1.25

52 Week Range

High
3.1688

Day Low 1.823
Company Name Stock Ticker Symbol Market Type
Xeris Biopharma Holdings Inc XERS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.08 4.4% 1.90 00:00:12
Open Price Low Price High Price Close Price Prev Close
1.86 1.823 1.94 1.87 1.82
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,479 917,777 $ 1.89 $ 1,733,716 - 1.25 - 3.1688
Last Trade Time Type Quantity Stock Price Currency
18:18:39 formt 200 $ 1.90 USD

Period:

Draw Mode:

Xeris Biopharma Holdings Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 257.51M 135.53M 121.07M $ 49.66M $ - -1.54 -1.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 380.00k 3.40%

more financials information »

Xeris Biopharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical XERS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.581.991.571.811,211,6220.3220.25%
1 Month1.471.991.361.60915,6840.4329.25%
3 Months2.202.421.361.751,398,397-0.30-13.64%
6 Months2.442.951.252.131,626,748-0.54-22.13%
1 Year2.603.16881.252.372,488,535-0.70-26.92%
3 Years10.6512.50391.253.552,005,901-8.75-82.16%
5 Years15.7527.98261.253.811,505,756-13.85-87.94%

Xeris Biopharma Description

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.


Your Recent History
NASDAQ
XERS
Xeris Biop..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now